Multi‐institutional experience with COVID‐19 convalescent plasma in children

Background and Objectives Convalescent COVID‐19 plasma (CCP) was developed and used worldwide as a treatment option by supplying passive immunity. Adult studies suggest administering high‐titer CCP early in the disease course of patients who are expected to be antibody‐negative; however, pediatric e...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Transfusion (Philadelphia, Pa.) Pa.), 2023-05, Vol.63 (5), p.918-924
Hauptverfasser:	Jacquot, Cyril, Gordon, Oren, Noland, Daniel, Donowitz, Jeffrey R., Levy, Emily, Jain, Sanjay, Willis, Zachary, Rimland, Casey, Loi, Michele, Arrieta, Antonio, Annen, Kyle, Drapeau, Noelle, Osborne, Stephanie, Ardura, Monica I., Arora, Satyam, Zivick, Elise, Delaney, Meghan
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Antibodies Blood Transfusion Child Child, Preschool Children COVID-19 COVID-19 - etiology COVID-19 - therapy COVID-19 Serotherapy COVID‐19 convalescent plasma Health services Humans Immunity (passive) Immunization, Passive - adverse effects Immunosuppression Infant Infant, Newborn Patients pediatric transfusion Pediatrics Prophylaxis Respiratory diseases Safety SARS-CoV-2 Transfusion transfusion safety
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background and Objectives Convalescent COVID‐19 plasma (CCP) was developed and used worldwide as a treatment option by supplying passive immunity. Adult studies suggest administering high‐titer CCP early in the disease course of patients who are expected to be antibody‐negative; however, pediatric experience is limited. We created a multi‐institutional registry to characterize pediatric patients (
ISSN:	0041-1132 1537-2995 1537-2995
DOI:	10.1111/trf.17318